| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a43ef275ae6f6fafc66975041eb60aa7 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5089
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5015
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1271
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1277
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1272 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-51 |
| filingDate |
2020-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_22a18a16557385be98baf4e2112aa933
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3af8ebd418f550aeb668cf9be2f2b660
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_69c83ead9c87f3e06ffcc1894fe6fabd |
| publicationDate |
2021-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2021008517-A |
| titleOfInvention |
Encapsulation of messenger RNA |
| abstract |
PROBLEM TO BE SOLVED: To provide a nanoparticle preparation containing lipid nanoparticles for encapsulating messenger RNA. A nanoparticle formulation comprising lipid nanoparticles encapsulating an mRNA encoding a cystic fibrosis conductance control protein, wherein the mRNA encoding the cystic fibrosis conductance control protein has a length of more than 4 kb. The lipid nanoparticles are encapsulated within the lipid nanoparticles with an encapsulation efficiency of 85% or greater, and the lipid nanoparticles have an average size of 80 nm or less and a homology scale (PDI) of 0.19 or less. Particle formulation. [Selection diagram] None |
| priorityDate |
2014-07-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |